1. Expert Perspectives on New Data in Multiple Sclerosis From the 2018 European MS Meeting

3. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Pregnancy and MS

5. Knowledge Gap Teratogenic Risks of DMTs

6. Reproductive Decision Making in MS

7. Reproductive Decision Making in MS (cont)

8. Reproductive History in a Danish Nationwide Study

9. Pregnancy Outcomes With Teriflunomide

10. Ocrelizumab and Pregnancy Outcomes

11. Concluding Remarks

12. Clinical Trial Data for Investigational Disease-Modifying Therapies for Relapsing MS

13. Ublituximab

14. Ublituximab in RRMS

15. Bruton Tyrosine Kinase Inhibitor

16. Evobrutinib Phase 2, 48-Week Study

17. Evobrutinib Safety Data

18. Cladribine Post-Hoc Analysis of CLARITY Data

19. Cladribine Post-Hoc Analysis of CLARITY Data (cont)

20. Practical Issues in Multiple Sclerosis

21. DMT Treatment Timing in RRMS

22. Predictors of Risk for Progression to SPMS

23. Comorbidities and MS

24. Acute Myocardial Infarction and MS

25. sNfL

26. Implementing sNfL Testing Into Practice

27. Long-Term Use of Disease-Modifying Therapies for Relapsing MS

28. Natalizumab, JCV, and PML

29. Natalizumab EID and Efficacy

30. Natalizumab EID and PML Risk

31. Saturation of CD49d With Natalizumab in EID

32. Alemtuzumab Long-Term Safety and Efficacy Data

33. Efficacy of Treatment Prospective 2-Year Study of Fingolimod and GA

34. Abbreviations

35. Abbreviations (cont)